# KL-A167

Source: https://onco.cc/drugs/kl-a167/  
OnCo record `kl-a167` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KL-A167 is an experimental investigational agent whose form is not stated in the registry from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for nasopharyngeal carcinoma and non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

KL-A167 is an investigational agent whose form is not stated in the registry developed by Sichuan Kelun-Biotech Biopharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05294172 (KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma), in nasopharyngeal carcinoma and non-small-cell lung cancer. The largest, NCT05294172, plans to enrol 295 participants (actual) with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody (KL-A167 is tagitanlimab; INN stem -mab; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of KL-A167: https://clinicaltrials.gov/search?intr=KL-A167

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)
- trials: [KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma](https://onco.cc/trials/nct05294172/), [SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.](https://onco.cc/trials/nct05351788/), [SKB500 Combinations in Patients With Small Cell Lung Cancer](https://onco.cc/trials/nct07296809/)

---
JSON: https://onco.cc/api/v1/entities/kl-a167.json